普洛药业 (000739.SZ) Latest Company News

Sep 4, 2026, 07:26 UTC
Puluo Pharmaceutical and others jointly established a new biotechnology company, Zhejiang Ante Yutai Biotechnology Co., Ltd., with registered capital of 10 million yuan.
Source:
- finance.sina.cn
Sep 3, 2026, 08:39 UTC
Apeloa Pharmaceutical announced it will provide financial assistance of 255 million yuan to its subsidiary Zhejiang Ante Yutai Biotechnology Co., Ltd., with related party Hengdian Co., Ltd. contributing 245 million yuan, at an annualized interest rate of 3% for up to three years.
Source:
- finance.sina.cn
Sep 2, 2026, 08:29 UTC
As of August 31, 2026, Zhejiang Apeloa Pharmaceutical Co., Ltd. had repurchased 5.4101 million shares for approximately 99.99 million yuan under its ongoing buyback program.
Source:
- finance.sina.cn
Aug 19, 2026, 11:06 UTC
Apeloa Pharmaceutical announced an interim cash dividend of 1.39 yuan per 10 shares (tax included), based on a total share capital of 1.126 billion shares after deducting 32.7673 million shares held in the repurchase account.
Source:
- finance.sina.cn
Aug 10, 2026, 07:55 UTC
Puluo Pharmaceutical's controlling subsidiary Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd. received a drug registration certificate from the National Medical Products Administration for pentoxifylline extended-release tablets, specification 0.4g, registration classification as chemical drug category 3, deemed to have passed generic drug consistency evaluation.
Source:
- finance.sina.cn
Aug 5, 2026, 09:38 UTC
Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Apeloa Pharmaceutical, received an approval notice from the National Medical Products Administration for the active pharmaceutical ingredient fluzelecept, in specifications of 20kg/barrel and 40kg/barrel.
Source:
- finance.sina.cn
Aug 3, 2026, 08:27 UTC
Puluo Pharmaceutical signed a five-year strategic cooperation framework agreement with Jitai Technology (Beijing) Co., Ltd. for long-term collaboration on CDMO services, potential capital and industrial synergy, and joint development of improved new drugs.
Source:
- finance.sina.cn
Jul 27, 2026, 10:38 UTC
The persons acting in concert with Apeloa Pharmaceutical's controlling shareholder increased their holdings by 6,057,900 shares, representing 0.52% of total share capital.
Source:
- finance.sina.cn

000739.SZ

Puluo Pharmaceutical and others jointly established a new biotechnology company, Zhejiang Ante Yutai Biotechnology Co., Ltd., with registered capital of 10 million yuan.

Apeloa Pharmaceutical announced it will provide financial assistance of 255 million yuan to its subsidiary Zhejiang Ante Yutai Biotechnology Co., Ltd., with related party Hengdian Co., Ltd. contributing 245 million yuan, at an annualized interest rate of 3% for up to three years.

As of August 31, 2026, Zhejiang Apeloa Pharmaceutical Co., Ltd. had repurchased 5.4101 million shares for approximately 99.99 million yuan under its ongoing buyback program.

Apeloa Pharmaceutical announced an interim cash dividend of 1.39 yuan per 10 shares (tax included), based on a total share capital of 1.126 billion shares after deducting 32.7673 million shares held in the repurchase account.

Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Apeloa Pharmaceutical, received an approval notice from the National Medical Products Administration for the active pharmaceutical ingredient fluzelecept, in specifications of 20kg/barrel and 40kg/barrel.

Puluo Pharmaceutical signed a five-year strategic cooperation framework agreement with Jitai Technology (Beijing) Co., Ltd. for long-term collaboration on CDMO services, potential capital and industrial synergy, and joint development of improved new drugs.

The persons acting in concert with Apeloa Pharmaceutical's controlling shareholder increased their holdings by 6,057,900 shares, representing 0.52% of total share capital.